The study of loading and release of N-acetylcystein by chitosan nanoparticles

Document Type : Original Article


Department of biotechnology, IROST, TEHRAN IRAN



N-acetylcysteine (NAC) is derived from acetylated cysteine as an oral medication. one of the serious problem of this drug is Initial dose reduction because it is metabolized in the intestine and liver. In the present study, N-acetylcysteine encapsulated in chitosan nanoparticles by gel method with sodium polyphosphate to study oral colon cancer therapy. NAC-chitosan nanoparticles synthesized spherical shape. Zeta potential and average size using laser light scattering (DLS) 31.4 mV and 133 nm, respectively. The drug encapsulation and loading efficiency of the nanoparticles were 79.8± 1.03% and 33 ± 2% respectively. In vitro, the amount of drug release from chitosan nanoparticles in PBS buffer after 48 hours was 69.2%. It is analysed toxicity of this drug on colon cancer cell lines by MTT method, It is shown that toxicity nanocapsulated NAC is more than free NAC. also viability of colon cancer cells treatment after 5 days decreased 92.2±2%. The results of this study could be a new way to increase the pharmacological effect of NAC particulate drug in delivery systems and reduce the dose in oral route.


[1] I. Dobrzynska, E. Skrzydlewska, I. Kasacka and Z. Figaszewski, J. Pharm Pharmacol., 52, 547-52 (2000).
[2] N. Vahdati-Mashhadian, M. R. Jafari, N. Sharghic and T. Sanati, J. Pharmaceutical Research., 12 (1), 141-146 (2013).
[3] P. Millea, J. Am Fam Physician., 80, 265–269 (2009).
[4] Y. Samuni, S. Goldstein, O. Dean and M. Berk, J. Biochim Biophys Acta., 1830(8), 4117–4129 (2013).
[5] R.K. Srivastava, Q. Rahman, M.P. Kashyap, M. Lohani and A.B. Pant. J. PLoS One., 6(9), e25767 (2011).
[6]. D. AKSIT, Y. ATICI, H. AKSIT, H. KARA, A. BILDIK, K.SEYREK , J. Acta Medica Mediterranea., 32, 337 (2016).
[7] O. Baysang, J. Neurochem., Jan. 2001.
[8] M.D. Neeley and L. Zimmerman, J. Free Radical. Biol Med., (2000).
[9] T. Ahmed, A.K. Tripathi, R.S. Ahmed, S. Das, S.G. Suke, R. Pathak, A. Chakraboti and B.D. Banerjee, J. Biochem Mol Toxicol., 22, 299-304 (2008).
[10] R. Vercelino, I. Crespo, G. de Souza, M. Cuevas, M. de Oliveira, N. Marroni, J. González-Gallego and M. Tuñón, J. Mol Med., 88. 401–411(2010)
[11] N. A. Kretzmann, E. Chiela, U. Matte, N. Marroni and C. A. Marroni, J. Comparative Hepatology., 11, 4 (2012).
[12] B. Ayfer, Ö.Ş. Ahmet, Z. O. Gülden, A. Serap, T. Pınar and Ş. Göksel, Int J Clin Exp Med., 10(7), 10031-10039 (2017).
[13] W. Paul and C. P. Sharma, J. Pharma Sciences, vol. 10, no. 1, pp. 5–22, 2000.
[14]  J.M. Dang and K.W. Leong, J. Advanced Drug Delivery Reviews., vol. 58, no. 4, pp. 487–499 (2006).
[15] K. A. Janes, P. Calvo, and M. J. Alonso, J. Advanced Drug Delivery Reviews, vol. 47, no. 1, pp. 83–97 ( 2001).
[16] M. M. G. Fouda, R. Wittke, D. Knittel, and E. Schollmeyer, J. International Journal of Diabetes Mellitus., vol. 1, no. 1, pp. 61–64 (2009).
[17]  L. Fan, H. Wu, H. Zhang, F. Li, T. Yang, C. Gu and Q. Yang, J. Carbohyd. Polym. 73, 390–400  (2008).
[18]  L. Zhu, J. Ma, N. Jia, Y. Zhao and H. Shen, J. Colloids Surf. B. Biointerfaces. 68, 1–6  (2009).
[19]  K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, and M. J. Alonso,  Journal of Controlled Release, vol. 73, no. 2-3, pp. 255–267(2001).
[20] V. Arulmozhia, K. Pandianb and S Mirunalini, J. Colloids and Surfaces B: Biointerfaces 110, 313– 320 (2013)
[21] S. Tı˘glı Aydın and M. Pulat, Journal of Nanomaterials, vol. 1,. 1,. 115–125 (2012).
[22]  S.K. Jain and A. Jain, J. Expert. Opin. Drug Deliv. 5, 483–498(2008).
[23]  R. Yang, W.S. Shim, F.D. Cui, G. Cheng, X. Han, Q.R. Jin, D.D. Kim, S.J. Chung, C.K. Shim, Int. J. Pharm. 371, 142–147(2009).